METHOCEL™ DC2: Designed for Speed, Simplicity and Performance

Through breakthrough technology, METHOCEL™ DC2 Premium Cellulose Ethers delivers up to 60 percent savings in process time and cost compared to wet granulation*, and achieves comparable or better performance in tablet properties and drug release for matrix formulations.

METHOCEL™ DC2, from the Colorcon and International Flavors and Fragrances Inc. Controlled Release Alliance, is an innovative particle-engineered hypromellose (HPMC) that is optimized to improve dry powder flow for use in direct compression. As a pure polymer, with no added ingredients or co-processed flow aids, METHOCEL™ DC2 meets all compendial requirements.

SPEED AND SIMPLICITY

Get to market faster with METHOCEL™ DC2:

- Bypasses time-consuming and labor-intensive wet granulation
- Saves processing time and cost
- Lower regulatory hurdles due to reduced manufacturing steps and complexity

METHOCEL™ DC2 accelerates the manufacturing process



Direct compression with METHOCEL™ DC2 can deliver 60% savings in processing time and cost while providing better protection for heat- and moisture-sensitive actives.

FLOW PERFORMANCE

- Better flow in formulation blends compared to traditional hypromellose-based formulations
- Uniform die-fill during tablet manufacturing provides tighter tablet weight control
- Improved process capability

METHOCEL™ DC2 reduces tablet weight variation



METHOCEL™ DC2 used in direct compression shows less variation in tablet weight over the tableting run than wet granulation processing.

* Actual results may vary based on formulation, manufacturing process, and local labor costs.

TABLETING PERFORMANCE

The engineered morphology of METHOCEL™ DC2 delivers:

- Consistent tablet attributes with reduced variability
- Good tablet mechanical strength for improved downstream processing
- Reproducible tablet properties at lab, pilot, and industrial scale

METHOCEL™ DC2 ensures good tablet mechanical properties



METHOCEL™ DC2 shows higher tablet hardness values when compared to wet granulation processing.

RELIABLE RELEASE PERFORMANCE

METHOCEL™ DC2 results in:

- Comparable or better tablet attributes
- Similar drug release profiles
- Savings in manufacturing steps and cost

Achieve similar and consistent drug release profile



Direct compression of low-dose indapamide with METHOCEL™ DC2 showed similar modified release performance compared with wet granulation (Hewlett, K. et al, AAPS, 2017).

Controlled Release Alliance

- IFF polymer chemistry expertise and manufacturing capability
- Colorcon dedicated team provides formulation expertise
- Colorcon local technical support for trials, scale-up and troubleshooting
- Colorcon global supply and logistics

Choose METHOCEL™ DC2 Premium Cellulose Ethers

For speed, simplicity and performance, choose METHOCEL™ DC2 and direct compression for matrix tablet manufacturing. Visit colorcon.com to learn more. To accelerate your product development, access Colorcon's expertise using HyperStart® Oral Solid Dose Starting Formulation Service.

Contact your Colorcon representative or call:

North America
+1-215-699-7733

Europe/Middle East/Africa
+44-(0)-1322-193000

Latin America
+54-11-5556-7700

India
+91-832-6727373

China
+86-21-61982300

You can also visit our website at
www.colorcon.com

Colorcon®

From Core to Coating, Your Supplier of Choice

This document is valid at the time of distribution. Distributed 14-Jul-2021 (UTC)